Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The CORKA trial which is looking at a functional home based rehabilitation programme for patients who may be at risk of poor outcome after knee arthroplasty compared to usual care has now recruited 100 participants.

CORKA is now actively recruiting at 4 sites across England – The Nuffield Orthopaedic Centre – Oxford, The Royal Orthopaedic Hospital – Birmingham, North Tyneside Hospital – Northumbria and Medway Maritime Hospital – Kent. There are plans to open 2 more sites by the end of March. Medway Community Hospital and Ashford and St Peter’s Hospital – Surrey.

The total number of participants needed for the CORKA trial is 635 and recruitment is ongoing until October 2016.

For more Information please visit http://corka.octru.ox.ac.uk/ or contact the CORKA trial team on 01865 737958 or email corka@ndorms.ox.ac.uk

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.